17 PATIENT COUNSELING INFORMATION
Inform patients of the risks associated with Argatroban Injection as well as the plan for regular monitoring during administration of the drug. Specifically, inform patients to report:
- •
- the use of any other products known to affect bleeding.
- •
- any medical history that may increase the risk for bleeding, including a history of severe hypertension; recent lumbar puncture or spinal anesthesia; major surgery, especially involving the brain, spinal cord, or eye; hematologic conditions associated with increased bleeding tendencies such as congenital or acquired bleeding disorders and gastrointestinal lesions such as ulcerations.
- •
- any bleeding signs or symptoms.
- •
- the occurrence of any signs or symptoms of allergic reactions (e.g., airway reactions, skin reactions and vasodilation reactions).
Manufactured by:
Gland Pharma Limited,
Hyderabad 500043, India.
Manufactured for:
Hospira Inc., Lake Forest, IL 60045 USA.
LAB-1207-3.0